Importantly, this also suggests that anti-CTLA4 or anti-PD-L1 immunotherapies might be worth exploring in the setting of early disease, where other mechanisms of immune evasion seen in advanced cancers may not have developed yet. The gene discussed is CTLA4; the disease is cancer.